Expertiseyou can count on

We are the UK’s largest independent laboratory-based CRO specialising in pre-clinical DMPK, quantitative bioanalysis, in vitro pharmacology and expert interpretation.

What we do

Through our consultative approach, the XenoGesis team helps to identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns, providing significant time and cost savings for our clients.

XenoGesis provides data-driven iterative feedback to our clients, and recommending next steps is a key focus. We combine our state-of-the-art in vitroin vivo and bioanalytical capabilities with expert PK/PD data interpretation services. This includes specific physiologically based pharmacokinetic (PBPK) modelling using GastroPlusTM. Our DMPK services demonstrate how the body may affect the way a drug behaves, backed-up with advice for how to modify the chemical structure of a compound to make it more ‘drug-like’. Our in vitro pharmacology, cytotoxicity and gene expression services can be customised for your project requirements. XenoGesis offers a flexible approach to working with our clients and services are offered on a fee-for-service or FTE basis.

XenoGesis was acquired by Sygnature Discovery in September 2020, find out more here.


Talk to a scientist... if you’d like to get in touch with one of our scientists, please click here!